Table 8.
Randomized controlled trial | Non-randomized controlled trial | ||||||||||||||||||||||||
CONSORT item | Bőthe et al. (2021) | Wainberg et al. (2006) | Hallberg et al. (2019) | Crosby and Twohig (2016) | Sniewski et al. (2020) | Wilson and Fischer (2018) | Savard et al. (2020) | Hallberg et al. (2020) | Hallberg et al. (2017) | Raymond et al. (2010) | Hartman et al. (2012) | Twohig and Crosby (2010) | Kjellgren (2018) | Holas et al. (2021) | Levin et al. (2017) | Hardy et al. (2010) | Gola and Potenza (2016) | Coleman et al. (2000) | Kafka and Hennen (2000) | Klontz et al. (2005) | Efrati and Gola (2018) | Orzack et al. (2006) | Hall et al. (2020) | Wan et al. (2000) | |
Title and abstract | 1a | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1b | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |
Background and objectives | 2a | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 0 |
2b | 2 | 1 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 0 | |
Trial design | 3a | 2 | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
3b | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Participants | 4a | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 2 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 |
4b | 0 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 2 | |
Interventions | 5 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2 | 1 | 1 |
Outcomes | 6a | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 1 | 1 |
6b | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Sample size | 7a | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7b | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Sequence generation | 8a | 2 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
8b | 2 | 2 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Allocation concealment mechanism | 9 | 2 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Implementation | 10 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blinding | 11a | 2 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11b | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Statistical methods | 12a | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
12b | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Participant flow | 13a | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 0 |
13b | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |||
Recruitment | 14a | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
14b | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Baseline data | 15 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 2 |
Numbers analysed | 16 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 |
Outcomes and estimation | 17a | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 1 |
17b | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
Ancillary analyses | 18 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Harms | 19 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 0 |
Limitations | 20 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 0 | 1 |
Generalisability | 21 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
Interpretation | 22 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
Registration | 23 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Protocol | 24 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Funding | 25 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 |
RoB Sum | 61 | 48 | 46 | 35 | 43 | 36 | 36 | 34 | 30 | 30 | 29 | 28 | 27 | 25 | 25 | 24 | 24 | 23 | 23 | 20 | 18 | 18 | 15 | 13 |
Note. Bold references have been included in the quantitative synthesis. We differentiate between randomized controlled trials and non-randomized controlled trials. Within these categories, references are sorted from lowest to highest risk of bias with higher sum scores indicating lower risk of bias. A detailed description of the CONSORT items can be retrieved from Moher et al. (2012). If an item was completely reported, it was rated with a score of ‘2’, if some information was missing, it was rated with ‘1’, if no information was given at all, it was rated with a score of ‘0’. This was also the case if the item was probably not applicable to the design. By this procedure studies which did not report a certain detail of the study were equally rated as studies which neglected this detail within the study design. 1a = Randomized trial in abstract, 1b = Structured abstract, 2a = Background/rationale, 2b = Objectives/hypotheses, 3a = Description, 3b = Changes, 4a = Eligibility criteria, 4b = Settings/locations data collection, 5 = For each group, 6a = Primary/secondary outcomes, 6b = Changes, 7a = How determined, 7b = Interim analyses/stopping guidelines, 8a = Method, 8b = Type of randomization, 9 = Mechanism, 10 = Who, 11a = Who blinded, 11b = Similarity of interventions, 12a = Statistical methods, 12b = Methods for additional analyses, 13a = Numbers of participants at each stage, 13b = Losses, exclusions, reasons, 14a = Dates defining the periods, 14b = Why the trial ended or was stopped, 15 = Table with characteristics, 16 = Number of participants, 17a = For each primary and secondary outcome, 17b = For binary outcomes, 18 = Results of any other analyses performed, 19 = All important harms or unintended effects, 20 = Trial limitations, 21 = Generalizability, 22 = Consistent with results, balanced, considering other relevant evidence, 23 = Registration number and name of trial registry, 24 = Where accessible, 25 = Sources of funding, role of funders, RoB = risk of bias assessment.